Ketamine to Prevent PPD After Cesarean
NCT04227704 · PoCKet · Washington University School of Medicine
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
The Prevalence of Postpartum Depression in the Study Population, as Defined as EPDS Greater Than 10 Out of 30
Measured over 42 days postpartum
Percentage of Eligible Patients Consenting to Participation
Measured over Through study completion, approximately 9 months
Percentage of Patients With a Complete Dataset
Measured over Through study completion, approximately 9 months
Number of Patients in Study Arms Experiencing One or More Severe Side Effects
Measured over Through study completion, approximately 9 months
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
1 study site
| Facility | City | Region | Country |
|---|---|---|---|
| Washington University in St. Louis | St Louis | Missouri | United States |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT04227704 on ClinicalTrials.gov →
Last updated in the registry 2023-01-26. Registry records change; this page reflects the data build of 2026-08-25.
Related